Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5‐year follow‐up

Ludwig, Heinz; Greil, Richard; Masszi, Tamas; Spicka, Ivan; Shpilberg, Ofer; Hajek, Roman; Dmoszynska, Anna; Paiva, Bruno; Vidriales, María-Belén; Esteves, Graca; Stoppa, Anne Marie; Robinson, Don Jr; van de Velde, Helgi; Chaturvedi, Shalini; Ataman, Ozlem; Enny, Christopher; Feng, Huaibao; Velde, Helgi; Viterbo, Luisa

Published in

Wiley, British Journal of Haematology, 3(171), p. 344-354, 2015

DOI: 10.1111/bjh.13582

Tools

Export citation

Search in Google Scholar

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5‐year follow‐up

Journal article published in 2015 by Heinz Ludwig, Richard Greil, Tamas Masszi, Ivan Spicka, Ofer Shpilberg, Roman Hajek, Anna Dmoszynska, Bruno Paiva

, María-Belén Vidriales

, Graca Esteves, Anne Marie Stoppa, Don Jr Robinson, Helgi van de Velde, Shalini Chaturvedi, Ozlem Ataman and other authors.

This paper is made freely available by the publisher.

Full text: Download

Preprint: archiving allowed

Upload

Postprint: archiving restricted

Upload

Published version: archiving forbidden

Policy details

Data provided by

Published in

Links

Tools

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5‐year follow‐up